Cagrilintide 5 mg/10 mg – Amylin analogue

What is Cagrilintide?

Cagrilintide (also known as AM833) is a synthetic, long-acting amylin analog. Amylin is a pancreatic hormone secreted together with insulin that acts via amylin receptors — complexes of the calcitonin receptor with RAMP proteins (AMY1–AMY3). The molecule is built on a human-amylin backbone with inspiration from calcitonin, and an attached fatty-acid residue provides reversible binding to albumin — which gives it a long half-life and enables once-weekly dosing.

Unlike incretin agonists such as Semaglutide (GLP-1), Tirzepatide (GLP-1/GIP) or Retatrutide (GLP-1/GIP/glucagon), Cagrilintide acts via a separate pathway — the amylin receptors in the central nervous system. This is why in the literature it is described not as a competitor of GLP-1 agonists but as their complementary partner — combining the two mechanisms (amylin + GLP-1) produces an additive effect in studies.

Cagrilintide is studied in the context of obesity and metabolic disorders — both as monotherapy and in combination with semaglutide. According to publicly available data it remains an experimental molecule and holds no registration as a standalone medicine. You will find the ready-made amylin + GLP-1 research combination with us as CS10 (Cagrilintide + Semaglutide). See also the other peptides for weight loss (GLP-1) in our category.

In the version offered by Peptology, Cagrilintide is supplied as a lyophilized research peptide with purity above 99% (HPLC/MS), confirmed by independent laboratory analysis (CoA for every batch), in a 5 mg/10 mg vial format. The product is intended exclusively for scientific research and in vitro applications and is not a medicinal product.

Available formats: 5 mg and 10 mg

Cagrilintide is available in lyophilized 5 mg and 10 mg formats, which cover typical research-work scales — from single in vitro series to longer protocols, including schedules combined with GLP-1 agonists.

The 5 mg and 10 mg formats have purity > 99% and a laboratory certificate for the batch. The choice of amount depends on the scale of the protocol, not on the concentration of the active substance.

How Cagrilintide works — amylin receptor agonism

In clinical and preclinical publications, Cagrilintide is described as a molecule that mimics the action of amylin by stimulating amylin receptors in the brain. These mechanisms act via a pathway separate from the incretins (GLP-1/GIP), and are described in the literature as signaling at the amylin receptors (AMY1, AMY3) and the calcitonin receptor.

Why the amylin pathway matters

Amylin and GLP-1 are two separate signaling pathways — they act via different receptors (amylin/calcitonin receptors and the GLP-1 receptor) and complement each other. This is why Cagrilintide is studied primarily as a partner to GLP-1 agonists, not as their replacement. In the combination study with semaglutide, adding the amylin axis to the GLP-1 axis produced greater body-weight reduction than either molecule alone.

This concept is being studied in an extensive clinical program (including phase 3 REDEFINE for the cagrilintide + semaglutide combination). The results presented come from controlled clinical trials and do not constitute a claim about the effect of the research-grade product.

Pharmacokinetics and pharmacodynamics of Cagrilintide

Cagrilintide is an acylated amylin analog which, in published pharmacokinetic data, is described as a molecule with a long half-life thanks to reversible binding to albumin — which explains the weekly dosing schedule used in clinical protocols.

• Biological half-life: about 7–8 days (~180 hours), which enables once-weekly dosing
• Long-action mechanism: reversible binding to albumin thanks to an attached fatty-acid residue (similar to semaglutide)
• Dosing schedule: once a week subcutaneously (SC), with dose titration over time
• Molecule class: amylin analog (amylin receptor agonist), separate from the GLP-1/GIP incretins
• Doses studied in phase 2 (monotherapy): 0.3–4.5 mg SC weekly, with titration from a lower dose

Cagrilintide vs Semaglutide vs CS10 (combination)

The table below compares Cagrilintide with a GLP-1 agonist and with the ready-made combination of both pathways. The key difference is one of class: Cagrilintide is an amylin analog (a separate pathway via amylin and calcitonin receptors), not an incretin agonist — which is why it is often combined with GLP-1 rather than compared as an alternative. The data are of a scientific-comparative nature and do not constitute a direct head-to-head comparison.

Sources: Lau et al., dose-finding phase 2 study of cagrilintide, The Lancet (2021, n=706); the REDEFINE 1/2 program for the cagrilintide + semaglutide combination (NEJM 2025). The data presented come from different clinical programs and should not be interpreted as a direct comparison or as a claim about the effect of a specific research-grade product.

Clinical trials of Cagrilintide

The clinical program of cagrilintide is developing along two lines — monotherapy (an amylin analog) and combination therapy with semaglutide. These results concern the clinically studied forms and come from controlled trials.

Phase 1 — safety and pharmacokinetics

Early clinical studies documented good tolerability with weekly dosing and a long half-life (~180 h) resulting from binding to albumin.

Phase 2 — monotherapy in obesity (The Lancet, 2021)

In a 26-week, dose-finding phase 2 study, 706 adults with obesity or overweight received cagrilintide at five doses (0.3–4.5 mg SC weekly), placebo or liraglutide 3.0 mg, together with a lifestyle change. The mean body-weight reduction was 6.0–10.8% in the cagrilintide groups versus 3.0% in the placebo group. These results come from a controlled clinical trial and do not constitute a recommendation for individual use.

REDEFINE 1 — combination with semaglutide (NEJM, 2025)

In the phase 3 REDEFINE 1 study (about 3400 adults with obesity without diabetes, 68 weeks), the cagrilintide + semaglutide combination produced a mean body-weight reduction of 20.4%, versus 11.5% for cagrilintide alone, 14.9% for semaglutide alone and 3% for placebo. A body-weight reduction of ≥ 20% was achieved by about 60% of participants in the combination group. These data illustrate the additive effect of combining both pathways and come from a controlled clinical trial.

REDEFINE 2 — combination in type 2 diabetes

The parallel REDEFINE 2 study evaluated the cagrilintide + semaglutide combination in adults with type 2 diabetes, documenting a significant body-weight reduction and improved glycemic control.

Note: The clinical trial information is presented for scientific and informational purposes and is based on published results. It does not constitute medical advice, a recommendation for use or a claim about the effect of the research-grade product offered by Peptology.

Documented clinical results for Cagrilintide

• Long-acting amylin analog — a separate pathway via amylin receptors, complementary to GLP-1 agonists
• Body-weight reduction of 6.0–10.8% in monotherapy in a dose-finding phase 2 study (Lancet, 2021)
• Up to 20.4% body-weight reduction in combination with semaglutide in the 68-week REDEFINE 1 study
• About 60% of participants with a ≥ 20% body-weight reduction in the combination group (REDEFINE 1)
• Additive amylin + GLP-1 effect — greater reduction than either molecule alone
• Long half-life (~180 h) thanks to albumin binding — once-weekly dosing

All results given concern published clinical trials of cagrilintide and its combination with semaglutide; they should not be interpreted as a promise of effect, an instruction for use or a claim about the effect of the research-grade product offered by Peptology.

Research dosing protocols

In clinical programs, cagrilintide was used in a weekly subcutaneous schedule with gradual dose titration — which aims to improve gastrointestinal tolerability:

• Phase 1 (dose escalation): a range of SC doses within the research protocol, with titration from a low dose
• Phase 2 (monotherapy, obesity): 0.3–4.5 mg SC once a week as the studied doses, with titration over up to 6 weeks
• Phase 3 (combination, REDEFINE): cagrilintide + semaglutide once a week SC, according to the protocol

Like the GLP-1 agonists — Semaglutide and Tirzepatide — Cagrilintide in studies requires slow titration to improve tolerability. In combination schedules it is paired with GLP-1; you will find the ready-made combination as CS10. These schedules are part of controlled clinical trials and do not constitute a recommendation for self-administration.

Storage and reconstitution

Cagrilintide is supplied as a lyophilized (freeze-dried) powder in a vial. In lyophilized form the peptide is stable at room temperature, protected from light and moisture — refrigeration before reconstitution is not mandatory. After reconstitution, stability depends on the solvent used, with Peptide Matrix Water™ significantly extending the peptide's lifespan.

• Before reconstitution: room temperature, in the original packaging, protected from light and moisture. A refrigerator is not mandatory.
• After reconstitution with Peptide Matrix Water™: stability in the refrigerator +2 °C to +8 °C for up to 60 days under appropriate laboratory conditions — the stabilizing formula extends the peptide's lifespan relative to standard solvents.
• After reconstitution with bacteriostatic or sterile water: stability in the refrigerator +2 °C to +8 °C for up to 28 days under appropriate conditions. Do not refreeze the reconstituted solution.
• Reconstitution: in a laboratory environment, Peptide Matrix Water™, bacteriostatic water or sterile water for injection is usually used, depending on the protocol.
• Volume: maximum 3 mL of solvent (capacity of a standard vial). For a precise calculation of volume and units, use the peptide calculator.
• Homogenization: add the solvent slowly down the vial wall, without vigorous shaking — peptide bonds are sensitive to mechanical stress. Swirl gently, do not shake.

Laboratory tip: With your order, you can add Peptide Matrix Water™ to the cart — a stabilizing solution designed for working with reconstituted research peptides. More in the article Bacteriostatic water vs acetic acid vs matrix water.

Frequently asked questions about Cagrilintide

What exactly is Cagrilintide?

Cagrilintide is a synthetic, long-acting amylin analog — a pancreatic hormone. It activates the amylin receptors (AMY1, AMY3) and the calcitonin receptor. It acts via a pathway separate from the GLP-1/GIP incretins. The results come from controlled clinical trials.

How does Cagrilintide differ from GLP-1 agonists?

GLP-1 agonists (such as Semaglutide) act on incretin receptors, while Cagrilintide — on amylin receptors. These are two separate signaling pathways, which is why Cagrilintide is studied mainly as a complementary partner to GLP-1, not as an alternative. Combination studies examine both pathways together.

What is the half-life of Cagrilintide?

The biological half-life of cagrilintide is about 7–8 days (~180 hours) thanks to reversible binding to albumin. This is why clinical protocols use a weekly schedule — similar to the GLP-1 agonists in our catalog.

How is Cagrilintide stored and reconstituted?

The lyophilized vial is stored at room temperature, protected from light and moisture — without the need for cooling before reconstitution. After reconstitution, stability depends on the solvent: with Peptide Matrix Water™ — up to 60 days in the refrigerator +2 °C to +8 °C; with bacteriostatic or sterile water — up to 28 days. Avoid refreezing.

Where to buy Cagrilintide for research?

Peptology offers Cagrilintide 5 mg as a research peptide with confirmed purity above 99% (HPLC/MS) and independent laboratory analysis for every batch. Fast shipping, discreet packaging and certificates of purity with the product. For scientific background, also see the article Peptides — what they are, how they work, main categories and safety profile.

Related peptides in the Peptology catalog

Researchers working with Cagrilintide often also consider GLP-1 / incretin agonists and ready-made combinations and solutions for reconstitution. Each of the products below has a certificate of purity above 99%:

See the full catalog: Peptides for weight loss (GLP-1) · Solutions for peptides · Blog on peptide research

Laboratory reconstitution

Laboratory protocol — reconstitution, research protocols, storage

Standardized protocol applicable to all research peptides in the Peptology catalogue. To calculate the solution concentration (mg/mL) for each vial, use the peptide reconstitution calculator.

60-second protocol

Quick reference

What you need

Five rules for reconstitution

Calculating concentration

Storage

Four mistakes to avoid

Shipping information

🚚 Shipping information

• Products in our warehouse – orders placed by 15:00 on working days are dispatched the same day, later orders on the next working day.

• Delivery with GLS to your address in 3–5 working days.

• Shipping costs €5 and is free from €50.

Frequently Asked Questions (FAQ)

In what form is Cagrilintide supplied and how should it be stored?

It is supplied as a lyophilized (freeze-dried) powder in a sealed vial. Store the unopened vial dry and protected from light, ideally at 2–8 °C. After laboratory reconstitution, keep the solution at 2–8 °C and use it within the period stated in the “Laboratory reconstitution” tab (up to 60 days with Peptide Matrix Water).

What purity does Cagrilintide have and how is it tested?

Every batch has a purity of 99% or higher, confirmed by HPLC and mass spectrometry (MS) and documented in a certificate of analysis (CoA). The report for the current batch is shown in the “Laboratory Analysis” tab.

Is a prescription required?

No. Offered for research purposes, without the need for a prescription.

Where can I buy Cagrilintide in Europe and what does it cost?

You can buy Cagrilintide in Europe online from Peptology, from 45,00 €. Delivery with GLS in 3–5 working days. Shipping is free from 50,00 €. Payment by card. Purity 99%+, with an HPLC report for every batch.

Laboratory Analysis

Cagrilintide - 5mg - Batch - 0226 - Purity

Cagrilintide - 10mg - Batch - 0226 - Purity